Rapid Micro Biosystems, Inc. (RPID)

Market Closed

1 Sep, 20:00

NASDAQ (CM)

1. 50

-0.02

-1.3158%

68.89M Market Cap

- P/E Ratio

- Div Yield

167,491 Volume

-1.27 Eps

$ 1.52

Previous Close

Investors:

Analysts:

Add Transaction

Day Range

1.47 1.53

Year Range

1.47 4.94

Want to track RPID and more in your Portfolio? 🎯

Get Started For Free

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 1 week ago

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 2 weeks ago

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Seekingalpha | 3 weeks ago

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems NASDAQ: RPID reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company's prior guidance, as consumable sales, service activity and recurring revenue increased.

Marketbeat | 3 weeks ago

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Zacks | 3 weeks ago

Rapid Micro Biosystems Q1 Earnings Call Highlights

Rapid Micro Biosystems NASDAQ: RPID reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while management said gross margin improvement remains a central priority for the year.

Marketbeat | 3 months ago

Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 months ago

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.26 per share a year ago.

Zacks | 3 months ago

What Makes Rapid Micro Biosystems (RPID) a New Buy Stock

Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 4 months ago

Rapid Micro Biosystems Q4 Earnings Call Highlights

Rapid Micro Biosystems (NASDAQ: RPID) reported fourth-quarter and full-year 2025 results highlighting record quarterly revenue, increased system placements, and expanding recurring revenue, while also outlining expectations for revenue growth and gross margin improvement in 2026. Fourth-quarter results set revenue and placement records Management said fourth-quarter revenue rose 37% year-over-year to a quarterly record of $11.3 million,

Defenseworld | 5 months ago

Rapid Micro Biosystems: Big Pharma Adoption Driving Growth

Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative margins and ongoing cash burn temper near-term optimism.

Seekingalpha | 5 months ago

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Seekingalpha | 5 months ago

Blog Affiliate Program About Terms Privacy Help Contact Us